Multiple Myeloma

Real-World Data Suggest Prolonged Lenalidomide Maintenance Therapy Is Beneficial in Patients With MRD-Positive Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date June 1, 2020

Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.

Depression/Antidepressant Use Associated With QOL but not OS in Patients With Hematologic Malignancies Undergoing HSCT, Study Finds

By

Susan Moench, PhD, PA-C

Publish Date May 22, 2020

This study separately evaluated the impact of depression/antidepressant use on the QOL and OS of cohorts of patients undergoing allogeneic or autologous HSCT.

Autologous Stem Cell Transplantation Outcomes in Multiple Myeloma vs Non-Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

Publish Date May 19, 2020

Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.

Practical Guidance for Managing Selinexor-Associated Adverse Events

By

Susan Moench, PhD, PA-C

Publish Date May 18, 2020

Involvement of nurses trained in the management of selinexor-associated AEs in patients with multiple myeloma is a key element of these recommendations.

Tocilizumab Shows Benefit in a Patient With COVID-19 and Multiple Myeloma

By

Victoria Forster, PhD

Publish Date May 14, 2020

IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.